Paclitero 260mg Injection

About Paclitero 260mg Injection

Paclitero 260mg Injection is an anticancer medication used to treat various cancers, including breast cancer, non-small cell lung cancer, ovarian cancer, and AIDS-related Kaposi's sarcoma. It works by interfering with the growth and division of cancer cells, helping to slow or stop their spread throughout the body. Depending on the type and stage of cancer, Paclitero 260mg Injection may be administered alone or in combination with other chemotherapy medicines to improve treatment outcomes. This medication is not recommended for patients with severe liver disease, uncontrolled infections, or significantly low white blood cell or platelet counts. It is also generally not suitable for children and adolescents under 18 years of age. Before starting treatment, patients should inform their healthcare provider about any history of heart disease or other underlying medical conditions, as close monitoring may be required. Serious allergic reactions can occur during administration, making medical supervision essential throughout treatment. Patients of reproductive age should use effective contraception during therapy and for at least six months after the final dose to prevent pregnancy-related risks. Additionally, because the formulation may contain alcohol, individuals with alcoholism or alcohol-related health conditions should discuss potential risks with their doctor before receiving Paclitero 260mg Injection.